PHARMACEUTICAL EXECUTIVE NEWSLETTER

In this ISSUE

England to Selectively Accelerate Innovation

Human Rights on the Pharma Risk Management Agenda

Women In Bio's “Boardroom Ready” Class of 2016 Graduates

Pricing and Reimbursement

Is More Competition the Cure in Pricing Debate?

Policymakers, payers and pharma companies weigh strategies for rationalizing drug prices. Jill Wechsler reports.
... /Read more/

Read this Front & Center article to see how your Hub can be a Secret Weapon to improve Outcomes.

Learn more

Reputation

Prix Galien Honors “Discoveries of the Decade”

Novartis and Bristol-Myers Squibb were among the companies honored with Prix Galien Foundation “Discovery of the Decade” Awards in New York last week.
... /Read more/

Emerging Markets

Biosimilar Trials Differ Notably from Innovator Studies

FDA officials agree that large comparative clinical trials defeat the purpose of the abbreviated development program for biosimilars.
... /Read more/

Regulatory Affairs

FDA Highlights “Flexibility” in Approving Rare Disease Therapies

The FDA approved Sarepta's Exondys for Duchenne muscular dystrophy despite little evidence of efficacy.
... /Read more/

Calendar

/ 7th Annual West Coast Compliance Congress /

/ Commercial Data Insights 2016 /

/ 3rd Annual Global Compliance Congress for Life Sciences /

/ 8th Annual Federal Pricing and Reporting /

/ GTN 2016 /

/ 2nd Annual Mobile Medical Apps Summit /

Regulatory Affairs

States Take Lead on Health, Drug Pricing Reform

One result of gridlock in Washington is that state governments are moving forward with policies and programs to address public concerns about affordable healthcare and soaring drug prices.
... /Read more/

update my profile / advertise with us / print & digital subscribe / visit pharmexec.com